Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.
2011 ◽
Vol 29
(15_suppl)
◽
pp. 3037-3037
◽
Keyword(s):
Phase I
◽
2005 ◽
Vol 58
(1)
◽
pp. 107-116
◽